

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LIQUIDIA TECHNOLOGIES, INC.,

Petitioner

v.

UNITED THERAPEUTICS CORPORATION,

Patent Owner.

---

Case IPR2020-00770

Patent No. 9,604,901

---

---

**Patent Owner's Mandatory Notices  
Under 37 C.F.R. § 42.8**

IPR2020-00770	Patent Owner Mandatory Notices
U.S. Patent No. 9,604,901	

Pursuant to 37 C.F.R. § 42.8, United Therapeutics Corporation (“United Therapeutics”) provides this Mandatory Notice within 21 days of service of the Petition (Paper 1) on March 31, 2020.

**I. Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8 (b)(1):**

United Therapeutics is the sole owner of U.S. Patent No. 9,604,901 (the “’901 patent”).

**II. Related Matters Pursuant to 37 C.F.R. § 42.8 (b)(2):**

US Ser. No. 16/594,737 is a pending continuation application with common priority to the ‘901 patent. IPR2020-00769 involves U.S. Patent No. 9,593,066 (the “’066 patent”), a patent with common priority to the ‘901 patent. United Therapeutics is not aware of any other related matters involving the ‘901 patent.

**III. Lead and Back-Up Counsel Pursuant to 37 C.F.R. §§ 42.8(b)(3):**

United Therapeutics designates the following Lead and Back-up Counsel:

Lead Counsel:

Stephen B. Maebius  
Foley & Lardner LLP  
3000 K St., NW, Suite 600  
Washington, DC 20007  
Direct Line: 202-672-5569  
Email: smaebius@foley.com  
Fax: 202-672-5399  
USPTO Reg. No. 35,264

IPR2020-00770	Patent Owner Mandatory Notices
U.S. Patent No. 9,604,901	

Backup Counsel:

George Quillin  
Foley & Lardner LLP  
3000 K St., NW, Suite 600  
Washington, DC 20007  
Direct Line: 202-672-5413  
Email: gquillin@foley.com  
Fax: 202-672-5399  
USPTO Reg. No. 32,792

Daniel R. Shelton  
Foley & Lardner LLP  
975 Page Mill Rd.  
Palo Alto, CA 94304  
Direct Line: 650-251-1119  
Email: dshelton@foley.com  
Fax: 650-856-3710  
USPTO Reg. No. 68,519

Shaun R. Snader  
United Therapeutics Corp.  
1735 Connecticut Ave., NW, 2<sup>nd</sup> Floor  
Washington, DC 20009  
Direct Line: 202-304-1701  
Email: ssnader@unither.com  
USPTO Reg. No. 59,987

Douglas Carsten  
Wilson, Sonsini, Goodrich & Rosati  
12235 El Camino Real  
Suite 200  
San Diego, CA 92130  
Direct Line: 858-350-2305  
Email: dcarsten@wsgr.com  
Fax: 858-350-2399  
USPTO Reg. No. 43,534

IPR2020-00770	Patent Owner Mandatory Notices
U.S. Patent No. 9,604,901	

Richard Torczon  
Wilson, Sonsini, Goodrich & Rosati  
1700 K Street NW, Floor 5  
Washington, DC 20006  
Direct Line: 202-973-8811  
Email: rtorczon@wsgr.com  
Fax: 202-973-8899  
USPTO Reg. No. 34,448

**IV. Service Information Pursuant to 37 C.F.R. §§ 42.8(b)(4):**

Please address all correspondence to the lead counsel at the address shown above. Patent Owner consents to electronic service by e-mail at:

SMaebius@foley.com and UTC-901@foley.com

Any questions concerning this paper may be directed to lead counsel.

Dated: April 17, 2020

Respectfully submitted,

/Stephen B. Maebius/  
Stephen B. Maebius  
Registration No. 35,264  
Counsel for Patent Owner

IPR2020-00770	Patent Owner Mandatory Notices
U.S. Patent No. 9,604,901	

### **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing **United Therapeutics Corporation's Mandatory Notices Under 37 C.F.R. § 42.8** was served on April 17, 2020, by email directed to the attorneys of record for the Petitioner at the following addresses:

zLiquidiaIPR@cooley.com<sup>1</sup>  
ielrifi@cooley.com  
emilch@cooley.com  
dkannappan@cooley.com

Dated: April 17, 2020

By: /Stephen B. Maebius/  
Stephen B. Maebius  
Registration No. 35,264  
Counsel for Patent Owner

---

<sup>1</sup> Patent Owner notes that this email address is listed in the petition filed against the '066 patent but not in the petition filed against the '901 patent.